PremiumThe FlyAtreca trading resumes Immunome to acquire antibody-related assets, materials from Atreca Atreca announces asset purchase agreement for sale of assets to Immunome PremiumThe FlyAtreca announces departure of CFO Cross, agreement to terminate lease Biotech Alert: Searches spiking for these stocks today Wedbush downgrades Atreca to Neutral following ATRC-101 discontinuation PremiumPre-EarningsAtreca (BCEL) Q1 Earnings Cheat Sheet Atreca price target lowered to $8 from $20 at Canaccord Atreca downgraded to In Line from Outperform at Evercore ISI 
